Mauna Kea: soaring after positive clinical results

(CercleFinance.com) - Mauna Kea's share price soared by over 12% this morning, following the announcement of unprecedented positive clinical results in lung cancer obtained with Cellvizio.


A recent clinical study published in the Journal of Thoracic Disease demonstrates the effectiveness of the combination of Cellvizio and Electromagnetic Navigation Bronchoscopy in improving the diagnosis and treatment of lung cancer.

With a sensitivity of 96.43% and a specificity of 100% in the characterization of malignant tumors, Cellvizio enabled improved diagnostic yield and targeting of nodules without irradiation for surgical resection.

'The results underline the potential of nCLE to quickly and accurately identify malignant lesions while minimizing the risks associated with traditional diagnostic methods, including ionizing radiation' says the group.

Professor Stéphane Renaud, thoracic surgeon at Nancy University Hospital and principal investigator of the study, said: 'We are extremely pleased with the results of this study, which highlight the great diagnostic value of needle endomicroscopy in combination with electromagnetic navigation bronchoscopy, and its ability to improve our treatment planning and minimize risks to the patient'.

Thanks to our improved ability to target biopsies, we have also been able to obtain essential tissue material for molecular and genomic analysis, which is fundamental to guiding immunotherapy strategies. This combination of technologies will certainly play a key role in the fight against lung cancer in the future. '

Copyright (c) 2024 CercleFinance.com. All rights reserved.